Early trials with FK 506 as primary treatment in liver transplantation
about
Liver transplantation: history, outcomes and perspectivesDoes tacrolimus offer virtual freedom from chronic rejection after primary liver transplantation? Risk and prognostic factors in 1,048 liver transplantations with a mean follow-up of 6 yearsA randomized trial of primary liver transplantation under immunosuppression with FK 506 vs cyclosporine.Adverse effects associated with the use of FK 506Comparative long-term evaluation of tacrolimus and cyclosporine in pediatric liver transplantation.Cytomegalovirus infection of the upper gastrointestinal tract following liver transplantation--incidence, location, and severity in cyclosporine- and FK506-treated patients.FK 506 conversion of renal allografts failing cyclosporine immunosuppressionFK 506 and autoimmune disease: perspective and prospects.Histopathology of human renal allograft rejection under FK 506: a comparison with cyclosporineClinical trial of FK 506 immunosuppression in adult cardiac transplantation.Liver transplantation of American veterans under FK 506 immunosuppression: a preliminary reportRandomized trial in primary liver transplantation under immunosuppression with FK 506 or cyclosporine.A clinical trial of FK 506 as primary and rescue immunosuppression in cardiac transplantation.The clinical trial of FK 506 as primary and rescue immunosuppression in adult cardiac transplantation.Kidney transplantation under FK 506Primary adult liver transplantation under tacrolimus: more than 90 months actual follow-up survival and adverse events.Tacrolimus (FK506) and the pharmaceutical/academic/regulatory gauntletA prospective trial of tacrolimus (FK 506) in clinical heart transplantation: intermediate-term resultsPreliminary experience with FK506 in thoracic transplantation.Renal dysfunction associated with liver transplantation.Past, present, and future prospects for inducing donor-specific transplantation tolerance for composite tissue allotransplantation.FK506 in solid organ transplantation.In-vitro interaction of a novel immunosuppressant, FK 506, and antacids.Effect of renal ischemia on plasma levels of FK 506 in rats.Superior rejection profile during the first 24 months after heart transplantation under tacrolimus as baseline immunosuppressive regimen.What have we learned about primary liver transplantation under tacrolimus immunosuppression? Long-term follow-up of the first 1000 patients.
P2860
Q26826902-8A7C4C64-8C7D-454E-975B-B32B1063B26DQ28344317-E5CFAB7E-688C-466E-BB6F-519008280A78Q34178467-CB7B3101-E696-4883-AB25-DA8C78ECFC5BQ34187736-59BA52A8-39D2-4D37-82B5-4A817BF029C3Q34231590-8DC99248-7402-4984-8E1D-CDA33DC6B477Q34232708-315E6777-2765-4DC5-87CE-9D5A904EAE2CQ34257151-1EE70C34-CEBC-457B-A145-D6A2C042C0AAQ34257329-F47CC401-66C4-47C7-891C-CFDF1D085D5CQ34259598-51E3292A-3037-4FEA-A4CB-20CADBED31CAQ34280863-DA0C5886-B696-453C-9FC4-0E32DD1DAE29Q34281070-F80F5F74-83AC-45E8-A3EA-0E51C0DF62DAQ34292111-6E05D585-0767-459D-859B-4CE12E33C416Q34298761-A3162EA6-BF34-4957-9148-A19DAB72D849Q34298800-4737F00E-EA26-4CA9-AE2F-381C1B6EF084Q34302082-5B6876F8-653F-48FB-9481-AB8A28A23EE0Q34304992-6B2706AA-41AF-4066-8CB1-CEC0AE68FA50Q34340969-6AFEA39F-9980-4D7A-9DFA-5A2079D485F4Q34498286-6F6A65A2-14B7-4A47-B936-CF5BAE44A3E8Q34546064-25A7CA66-DCEA-43C9-956A-ADACE76FA76FQ36680260-4C9B8EB9-3361-4A34-978B-C1A6BC3AA171Q40159236-FFF9F04D-BA65-46E7-9AA1-4FEB5DAA2D38Q40962151-9CC58BE9-630A-4FCC-AA74-7753F92F61CAQ41998451-10E50DAF-7B50-48B0-B63E-9A706142FFFCQ42410291-AF3251DE-E54B-44D1-92DD-68000ACA06BBQ46590316-5BDAAFE7-E480-401A-BC17-5C8E0F18C6AAQ54078474-8C89023B-FA3D-4426-93CC-632FE2665B46
P2860
Early trials with FK 506 as primary treatment in liver transplantation
description
1990 nî lūn-bûn
@nan
1990 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
1990 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
1990年の論文
@ja
1990年論文
@yue
1990年論文
@zh-hant
1990年論文
@zh-hk
1990年論文
@zh-mo
1990年論文
@zh-tw
1990年论文
@wuu
name
Early trials with FK 506 as primary treatment in liver transplantation
@ast
Early trials with FK 506 as primary treatment in liver transplantation
@en
type
label
Early trials with FK 506 as primary treatment in liver transplantation
@ast
Early trials with FK 506 as primary treatment in liver transplantation
@en
prefLabel
Early trials with FK 506 as primary treatment in liver transplantation
@ast
Early trials with FK 506 as primary treatment in liver transplantation
@en
P2093
P2860
P50
P1476
Early trials with FK 506 as primary treatment in liver transplantation
@en
P2093
P2860
P407
P577
1990-02-01T00:00:00Z